OVID THERAPEUTICS INC

Ovid Therapeutics Inc. (http://www.ovidrx.com/) is a biopharmaceutical company focused on developing medicines for patients and families living with rare neurological disorders. The Company's product pipeline includes two late-stage programs and several early-stage programs. The product candidates in its pipeline includes OV935 (soticlestat), OV329, OV882 and OV815. Soticlestat, which is under late-stage program, is for the treatment of dravet syndrome and lennox-gastaut syndrome. OV329, which is under late-stage program, is focused on treatment of seizures associated with tuberous sclerosis complex and infantile spasms. OV882, which is under early-stage program, is for the treatment of angelman syndrome and is being developed in collaboration with the University of Connecticut School of Medicine. OV815 is for the treatment of KIF1A Associated Neurological Disorder (KAND) and is being developed in collaboration with Columbia University Irving Medical Center.

• OVID THERAPEUTICS INC